Enomoto Hirayuki

Affiliation and department：

Research field (1)： Gastroenterology

Research theme for competitive and other funds (7)：

2021 - 2024 核酸医薬を応用した肝癌由来増殖因子を標的とする新たな肝細胞癌治療薬の開発
2021 - 2024 Clarify the role of mitochondria function on the development of fatty liver and hepatic carcinogenesis by targeting Apop-1
2016 - 2020 Development of new treatment for liver cancer by the functional analysis of the hepatoma-derived growth factor and its receptor, nucleolin
2013 - 2016 The role of impaired micro circulation or coagulopathy in chronic liver disease
2012 - 2016 Role of hepatoma-derived growth factor in the tumor angiogenesis and the growth of the hepatocellular carcinoma

Show all

Papers (197)：

Toru Nakamura, Atsutaka Masuda, Makoto Kako, Hirayuki Enomoto, Masaki Kaibori, Yasuyuki Fujita, Kyoko Tanizawa, Tetsuya Ioji, Yoshihiro Fujimori, Kei Fukami, et al. Hepatic arterial infusion of autologous CD34+ cells for hepatitis C virus-related decompensated cirrhosis: A multicenter, open-label, exploratory randomized controlled trial. Regenerative therapy. 2024. 27. 455-463
Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, et al. Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial. Alimentary pharmacology & therapeutics. 2024
Natsuko Kobayashi, Toshifumi Tada, Takashi Nishimura, Tomomitsu Matono, Yukihisa Yuri, Tomoyuki Takashima, Nobuhiro Aizawa, Naoto Ikeda, Shinya Fukunishi, Mariko Hashimoto, et al. Metabolic dysfunction-associated steatotic liver disease criteria may underestimate the number of lean female nonalcoholic fatty liver disease patients with significant liver fibrosis. Hepatology research : the official journal of the Japan Society of Hepatology. 2024. 54. 5. 429-438
Hirayuki Enomoto, Norio Akuta, Hayato Hikita, Goki Suda, Jun Inoue, Nobuharu Tamaki, Kiyoaki Ito, Takemi Akahane, Tomokazu Kawaoka, Asahiro Morishita, et al. Etiological changes of liver cirrhosis and hepatocellular carcinoma-complicated liver cirrhosis in Japan: Updated nationwide survey from 2018 to 2021. Hepatology research : the official journal of the Japan Society of Hepatology. 2024
Tomomitsu Matono, Toshifumi Tada, Takashi Nishimura, Tomoyuki Takashima, Nobuhiro Aizawa, Naoto Ikeda, Hideyuki Shiomi, Hirayuki Enomoto, Hiroko Iijima. VFMAP predicted hepatocellular carcinoma development in patients with chronic hepatitis C who were treated with direct-acting antiviral and achieved sustained virologic response. Journal of medical ultrasonics (2001). 2024. 51. 2. 293-300

ｍore...

MISC (59)：

西村貴士, 吉田昌弘, 東浦晶子, 榎本平之, 飯島尋子. 特集肝疾患-診療のチェックポイント2023 第I部診断のチェックポイント第4章肝画像診断のチェックポイント 1.肝障害患者のエコーによる肝疾患画像. 臨床消化器内科. 2023. 38. 7. 774-783
榎本平之, 飯島尋子. 特集ウイルス肝炎制御時代の肝発癌 1.ウイルス肝炎制御をめぐる疫学と最新動向(4)わが国における肝硬変成因の動向. 臨床消化器内科. 2022. 37. 8. 888-893
榎本平之, 西口修平. 疫学自己免疫性肝疾患の疫学-Epidemiology of the autoimmune liver diseases-特集自己免疫性肝疾患 : 自己免疫性肝炎,原発性胆汁性胆管炎,原発性硬化性胆管炎. 日本臨床 = Japanese journal of clinical medicine. 2020. 78. 1. 52-57
西村貴士, 西村貴士, 橋本眞里子, 中野智景, 青木智子, 高嶋智之, 會澤信弘, 池田直人, 榎本平之, 中島収, et al. 多血性肝腫瘍に対するSuperb Microvascular Imagingの有用性. Rad Fan. 2019. 17. 5
青木智子, 青木智子, 飯島尋子, 飯島尋子, 西村貴士, 高嶋智之, 會澤信弘, 池田直人, 榎本平之, 藤元治朗, et al. 超音波SWEを用いた肝硬変診療のこころみ. 肝臓. 2019. 60. Supplement 2

ｍore...

Lectures and oral presentations (7)：

【第52回超音波ドプラ・新技術研究会臨床報告集超音波愛(AI・EYE)】計測領域自動設定機能を有したUGAP(Ultrasound-Guided Attenuation Parameter)による肝脂肪化診断
(Rad Fan 2024)
高齢化がすすむC型肝炎SVR例における肝発癌予測としてのFIB-3 indexの有用性
(肝臓 2024)
消化器領域に対するエラストグラフィの進歩門脈圧亢進症におけるエラストグラフィの役割
(超音波医学 2024)
自己免疫性肝疾患の病態解明と診療展開自己免疫性肝炎におけるMASLD合併の影響
(日本消化器病学会雑誌 2024)
肝硬変の新しい診断法とリスク評価 NASH/NAFLDにおける肝発癌リスク因子としてスコアリングシステムの有用性
(日本消化器病学会雑誌 2024)

ｍore...

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page